# Multiple myeloma

The EU has approved 39 indications of 18 drugs in multiple myeloma. None of them needs a biomarker result.

## Approved indications

### No biomarker required

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Bortezomib](https://oncolabels.com/drugs/bortezomib) (Velcade) | None | + dexamethasone, or with dexamethasone and thalidomide | Induction | Eligible for high-dose chemotherapy with haematopoietic stem cell transplantation |
| [Bortezomib](https://oncolabels.com/drugs/bortezomib) (Velcade) | None | + melphalan and prednisone | 1st line | Ineligible for high-dose chemotherapy with haematopoietic stem cell transplantation |
| [Daratumumab](https://oncolabels.com/drugs/daratumumab) (Darzalex) | None | + bortezomib, lenalidomide and dexamethasone | 1st line | - |
| [Daratumumab](https://oncolabels.com/drugs/daratumumab) (Darzalex) | None | + bortezomib, thalidomide and dexamethasone | 1st line | Eligible for autologous stem cell transplant |
| [Daratumumab](https://oncolabels.com/drugs/daratumumab) (Darzalex) | None | + lenalidomide and dexamethasone, or bortezomib, melphalan and prednisone | 1st line | Ineligible for autologous stem cell transplant |
| [Isatuximab](https://oncolabels.com/drugs/isatuximab) (Sarclisa) | None | + bortezomib, lenalidomide, and dexamethasone | 1st line | Transplant-ineligible |
| [Isatuximab](https://oncolabels.com/drugs/isatuximab) (Sarclisa) | None | + bortezomib, lenalidomide, and dexamethasone | Induction | Transplant-eligible |
| [Lenalidomide](https://oncolabels.com/drugs/lenalidomide) (Revlimid) | None | + dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone | 1st line | Transplant-ineligible |
| [Thalidomide](https://oncolabels.com/drugs/thalidomide) (Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed) | None | + melphalan and prednisone | 1st line | Aged ≥ 65 years or ineligible for high dose chemotherapy |
| [Lenalidomide](https://oncolabels.com/drugs/lenalidomide) (Revlimid) | None | Monotherapy | Maintenance | After autologous stem cell transplantation |
| [Belantamab mafodotin](https://oncolabels.com/drugs/belantamab-mafodotin) (Blenrep) | None | + bortezomib and dexamethasone | 2nd line | After at least one prior therapy; Relapsed or refractory |
| [Belantamab mafodotin](https://oncolabels.com/drugs/belantamab-mafodotin) (Blenrep) | None | + pomalidomide and dexamethasone | 2nd line | After at least one prior therapy including lenalidomide; Relapsed or refractory |
| [Bortezomib](https://oncolabels.com/drugs/bortezomib) (Velcade) | None | + pegylated liposomal doxorubicin or dexamethasone | 2nd line | After at least 1 prior therapy; Progressive disease; have already undergone or are unsuitable for haematopoietic stem cell transplantation |
| [Bortezomib](https://oncolabels.com/drugs/bortezomib) (Velcade) | None | Monotherapy | 2nd line | After at least 1 prior therapy; Progressive disease; have already undergone or are unsuitable for haematopoietic stem cell transplantation |
| [Carfilzomib](https://oncolabels.com/drugs/carfilzomib) (Kyprolis) | None | + daratumumab and dexamethasone | 2nd line | After at least one prior therapy |
| [Carfilzomib](https://oncolabels.com/drugs/carfilzomib) (Kyprolis) | None | + dexamethasone | 2nd line | After at least one prior therapy |
| [Carfilzomib](https://oncolabels.com/drugs/carfilzomib) (Kyprolis) | None | + lenalidomide and dexamethasone | 2nd line | After at least one prior therapy |
| [Ciltacabtagene autoleucel](https://oncolabels.com/drugs/ciltacabtagene-autoleucel) (Carvykti) | None | Monotherapy | 2nd line | After at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor; disease progression on the last therapy; refractory to lenalidomide |
| [Daratumumab](https://oncolabels.com/drugs/daratumumab) (Darzalex) | None | + lenalidomide and dexamethasone, or bortezomib and dexamethasone | 2nd line | After at least one prior therapy |
| [Daratumumab](https://oncolabels.com/drugs/daratumumab) (Darzalex) | None | + pomalidomide and dexamethasone | 2nd line | After one prior therapy containing a proteasome inhibitor and lenalidomide with lenalidomide refractoriness, or at least two prior therapies including lenalidomide and a proteasome inhibitor with disease progression on or after the last therapy |
| [Daratumumab](https://oncolabels.com/drugs/daratumumab) (Darzalex) | None | Monotherapy | 2nd line | After prior therapy included a proteasome inhibitor and an immunomodulatory agent, and demonstrated disease progression on the last therapy |
| [Elotuzumab](https://oncolabels.com/drugs/elotuzumab) (Empliciti) | None | + lenalidomide and dexamethasone | 2nd line | After at least one prior therapy |
| [Isatuximab](https://oncolabels.com/drugs/isatuximab) (Sarclisa) | None | + carfilzomib and dexamethasone | 2nd line | After at least one prior therapy |
| [Ixazomib](https://oncolabels.com/drugs/ixazomib) (Ninlaro) | None | + lenalidomide and dexamethasone | 2nd line | After at least one prior therapy |
| [Lenalidomide](https://oncolabels.com/drugs/lenalidomide) (Revlimid) | None | + dexamethasone | 2nd line | After at least one prior therapy |
| [Pomalidomide](https://oncolabels.com/drugs/pomalidomide) (Imnovid (previously Pomalidomide Celgene)) | None | + bortezomib and dexamethasone | 2nd line | After at least one prior treatment regimen including lenalidomide |
| [Selinexor](https://oncolabels.com/drugs/selinexor) (Nexpovio) | None | + bortezomib and dexamethasone | 2nd line | After at least one prior therapy |
| [Teclistamab](https://oncolabels.com/drugs/teclistamab) (Tecvayli) | None | + daratumumab | 2nd line | After at least one prior therapy; Relapsed or refractory |
| [Elotuzumab](https://oncolabels.com/drugs/elotuzumab) (Empliciti) | None | + pomalidomide and dexamethasone | 3rd line+ | After at least two prior therapies including lenalidomide and a proteasome inhibitor, with disease progression on the last therapy |
| [Elranatamab](https://oncolabels.com/drugs/elranatamab) (Elrexfio) | None | Monotherapy | 3rd line+ | After at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and demonstrated disease progression on the last therapy |
| [Idecabtagene vicleucel](https://oncolabels.com/drugs/idecabtagene-vicleucel) (Abecma) | None | Monotherapy | 3rd line+ | After at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, with disease progression on the last therapy |
| [Isatuximab](https://oncolabels.com/drugs/isatuximab) (Sarclisa) | None | + pomalidomide and dexamethasone | 3rd line+ | After at least two prior therapies including lenalidomide and a proteasome inhibitor, with disease progression on the last therapy |
| [Linvoseltamab](https://oncolabels.com/drugs/linvoseltamab) (Lynozyfic) | None | Monotherapy | 3rd line+ | After at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and disease progression on the last therapy; Relapsed and refractory |
| [Panobinostat](https://oncolabels.com/drugs/panobinostat) (Farydak) | None | + bortezomib and dexamethasone | 3rd line+ | After at least two prior regimens including bortezomib and an immunomodulatory agent |
| [Pomalidomide](https://oncolabels.com/drugs/pomalidomide) (Imnovid (previously Pomalidomide Celgene)) | None | + dexamethasone | 3rd line+ | After at least two prior treatment regimens, including both lenalidomide and bortezomib, and disease progression on the last therapy; Relapsed and refractory |
| [Selinexor](https://oncolabels.com/drugs/selinexor) (Nexpovio) | None | + dexamethasone | 3rd line+ | After at least four prior therapies; refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, with disease progression on the last therapy |
| [Talquetamab](https://oncolabels.com/drugs/talquetamab) (Talvey) | None | Monotherapy | 3rd line+ | After at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and demonstrated disease progression on the last therapy |
| [Teclistamab](https://oncolabels.com/drugs/teclistamab) (Tecvayli) | None | Monotherapy | 3rd line+ | After at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody; disease progression on the last therapy; Relapsed and refractory |
| [Daratumumab](https://oncolabels.com/drugs/daratumumab) (Darzalex) | None | Monotherapy | Any line | Smouldering myeloma only (high risk); High risk of developing multiple myeloma |

## Label wording

- **Ciltacabtagene autoleucel** (Carvykti), Multiple myeloma, 2nd line: “CARVYKTI is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/carvykti-epar-product-information_en.pdf)
- **Pomalidomide** (Imnovid (previously Pomalidomide Celgene)), Multiple myeloma, 2nd line: “Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/imnovid-epar-product-information_en.pdf)
- **Pomalidomide** (Imnovid (previously Pomalidomide Celgene)), Multiple myeloma, 3rd line+: “Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/imnovid-epar-product-information_en.pdf)
- **Teclistamab** (Tecvayli), Multiple myeloma, 2nd line: “in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf)
- **Teclistamab** (Tecvayli), Multiple myeloma, 3rd line+: “as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf)
- **Belantamab mafodotin** (Blenrep), Multiple myeloma, 2nd line: “in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy” [SmPC](https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf)
- **Belantamab mafodotin** (Blenrep), Multiple myeloma, 2nd line: “in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdf)
- **Daratumumab** (Darzalex), Multiple myeloma, 1st line: “in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf)
- **Daratumumab** (Darzalex), Multiple myeloma, 1st line: “in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf)
- **Daratumumab** (Darzalex), Multiple myeloma, 2nd line: “in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf)
- **Daratumumab** (Darzalex), Multiple myeloma, 2nd line: “as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf)
- **Daratumumab** (Darzalex), Multiple myeloma, 1st line: “in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf)
- **Daratumumab** (Darzalex), Multiple myeloma, 2nd line: “in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf)
- **Daratumumab** (Darzalex), Multiple myeloma, any line: “DARZALEX as monotherapy is indicated for the treatment of adult patients with smouldering multiple myeloma at high risk of developing multiple myeloma (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf)
- **Ixazomib** (Ninlaro), Multiple myeloma, 2nd line: “NINLARO in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/ninlaro-epar-product-information_en.pdf)
- **Selinexor** (Nexpovio), Multiple myeloma, 2nd line: “in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf)
- **Selinexor** (Nexpovio), Multiple myeloma, 3rd line+: “in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/nexpovio-epar-product-information_en.pdf)
- **Carfilzomib** (Kyprolis), Multiple myeloma, 2nd line: “Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf)
- **Carfilzomib** (Kyprolis), Multiple myeloma, 2nd line: “Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf)
- **Carfilzomib** (Kyprolis), Multiple myeloma, 2nd line: “Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/kyprolis-epar-product-information_en.pdf)
- **Isatuximab** (Sarclisa), Multiple myeloma, 3rd line+: “in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/sarclisa-epar-product-information_en.pdf)
- **Isatuximab** (Sarclisa), Multiple myeloma, 2nd line: “in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/sarclisa-epar-product-information_en.pdf)
- **Isatuximab** (Sarclisa), Multiple myeloma, 1st line: “in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/sarclisa-epar-product-information_en.pdf)
- **Isatuximab** (Sarclisa), Multiple myeloma, induction: “in combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/sarclisa-epar-product-information_en.pdf)
- **Lenalidomide** (Revlimid), Multiple myeloma, maintenance: “Revlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf)
- **Lenalidomide** (Revlimid), Multiple myeloma, 1st line: “Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf)
- **Lenalidomide** (Revlimid), Multiple myeloma, 2nd line: “Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf)
- **Bortezomib** (Velcade), Multiple myeloma, 2nd line: “VELCADE as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf)
- **Bortezomib** (Velcade), Multiple myeloma, 2nd line: “VELCADE as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf)
- **Bortezomib** (Velcade), Multiple myeloma, 1st line: “VELCADE in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf)
- **Bortezomib** (Velcade), Multiple myeloma, induction: “VELCADE in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf)
- **Elranatamab** (Elrexfio), Multiple myeloma, 3rd line+: “ELREXFIO is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/elrexfio-epar-product-information_en.pdf)
- **Idecabtagene vicleucel** (Abecma), Multiple myeloma, 3rd line+: “Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/abecma-epar-product-information_en.pdf)
- **Talquetamab** (Talvey), Multiple myeloma, 3rd line+: “TALVEY is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/talvey-epar-product-information_en.pdf)
- **Panobinostat** (Farydak), Multiple myeloma, 3rd line+: “Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/farydak-epar-product-information_en.pdf)
- **Elotuzumab** (Empliciti), Multiple myeloma, 2nd line: “Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/empliciti-epar-product-information_en.pdf)
- **Elotuzumab** (Empliciti), Multiple myeloma, 3rd line+: “Empliciti is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy (see sections 4.2 and 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/empliciti-epar-product-information_en.pdf)
- **Thalidomide** (Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed), Multiple myeloma, 1st line: “Thalidomide BMS in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/thalidomide-bms-epar-product-information_en.pdf)
- **Linvoseltamab** (Lynozyfic), Multiple myeloma, 3rd line+: “LYNOZYFIC is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/lynozyfic-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/multiple-myeloma